What do systematic reviews say?

Arterial thromboembolism ‐ not measured · people with COVID‐19

Acute respiratory distress syndrome ‐ not measured · people with COVID‐19

Mortality ‐ not measured · people with COVID‐19

Proportion of participants reporting no worse than mild pain by 14 days after start of treatment · adults with cancer‐related pain

Quality of life · non‐hospitalised adults with mild COVID‐19

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with clinically diagnosed seizures

Proportion of infants who achieve seizure control after the first loading dose of ASM · neonates with EEG‐confirmed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with EEG‐confirmed seizures

Proportion of infants who achieve seizure control after maximal loading dose of ASM · neonates with clinically diagnosed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with clinically diagnosed seizures

Proportion of infants who achieve seizure control after maximal loading dose of ASM · neonates with clinically diagnosed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with clinically diagnosed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with EEG‐confirmed seizures

Proportion of infants who achieve seizure control after maximal loading dose of ASM · neonates with clinically diagnosed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with clinically diagnosed seizures

Proportion of infants who achieve seizure control after maximal loading dose of ASM · neonates with EEG‐confirmed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with EEG‐confirmed seizures

Proportion of infants who achieve seizure control after the first loading dose of ASM · neonates with EEG‐confirmed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with clinically diagnosed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates